Crispr Therapeutics AG (CRSP) has provided an update.
CRISPR Therapeutics AG shareholders endorsed key proposals at their 2024 Annual General Meeting, notably the expansion of their 2018 Stock Option and Incentive Plan by an additional 1 million shares and amendments to their Articles of Association to better align with current market practices for equity compensation and pension benefits. Additionally, they approved the financial statements and management report for 2023, the re-election of board members and auditors, and various compensation packages for board directors and executive officers, demonstrating strong shareholder involvement in the company’s governance and strategic incentive plans.
For detailed information about CRSP stock, go to TipRanks’ Stock Analysis page.
